A new class of non-opioid drugs treats pain by blocking signals before they reach the brain, reducing the risk of addiction.

People undergoing hemodialysis treatment for kidney failure often experience chronic pain related to their condition, but it ...

Suzetrigine, to be sold under the brand name Journavx, is the first new type of pain medicine approved by the FDA in more ...

How do you determine if spine surgery is necessary for someone of his age, and what are the potential risks and rewards of such surgery compared to conservative treatments for his condition? Spine ...

The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.

The US Food and Drug Administration has approved a new, nonopioid pain medication for treating moderate to severe acute pain.

Medically reviewed by Stella Bard, MD Osteoarthritis (OA) and rheumatoid arthritis (RA) are two of the most common types of ...

The FDA recently approved Vertex Pharmaceuticals Incorporated’s Journavx (suzetrigine), a first-in-class non-opioid medication for treating moderate to severe acute pain in adults. Journavx, approved ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis (CF) treatments, finds itself at a ...

While GLP-1 therapies like Ozempic gain traction, personalized peptide therapies are supporting long-term health goals ...

Lieutenant Governor Manoj Sinha inaugurated the 32nd International Conference of the Indian Association of Palliative Care ...

South San Francisco, CA, January 30, 2025 – The California Institute for Regenerative Medicine (CIRM), one of the world’s largest institutions dedicated to regenerative medicine, has awarded nearly ...